Oncology is a study of the treatment of tumors and cancers.
GCC Oncology/Cancer Drugs Market Analysis, 2020 research report depicts a deep-dive market analysis of statistics of the GCC Oncology/Cancer Drugs market which consists of regional and country-wise market size, market forecast, CAGR market segmentation, market shares of diverse regions and countries, market share of various end-users, applications, product type, technologies, competitive benchmarking, etc.
According to MarkNtel Advisors’ research report titled “GCC Oncology/Cancer Drugs Market Analysis, 2020”, the GCC Oncology/Cancer Drugs market is anticipated to grow at a considerable CAGR during 2020-25 owing to the rising incidences of patients diagnosed with cancer and surging initiative to reduce the number of deaths due to cancer. According to The UAE National Health Agenda 2021, the UAE targets to reduce cancer deaths to about 64.2 per 100,000 of the population by 2021.
Breast Cancer Acquired the Highest Market Share
Breast cancer is among the leading reasons for death of women in the region. In UAE, 1,054 new cases of breast cancer were registered in 2018. Women around the age of 40 and above are likely to develop breast cancer. In order to reduce the overall mortality rate, various steps are being taken by the governments for the production of oncology drugs for breast cancer. Besides this, numerous Breast Cancer Awareness and Prevention programs are also initiated by the governments in the region in order to spread awareness amongst women about the disease and to enable them toward early detection and diagnosis, prevention, and treatment methods. Thus, these factors are expected to catalyze the market growth of Oncology/Cancer Drugs in the forecast period as stated in the MarkNtel Advisors’ research report “GCC Oncology/Cancer Drugs Market Analysis, 2020”.
Targeted Therapy Exhibited the Fastest Growth
Based on Therapy, Targeted Therapy is anticipated to attain the highest CAGR in the forthcoming years. The growth is attributed to bolstering cases of breast cancer. Targeted therapy is widely used for the treatment of breast cancer by targeting cellular processes to stop the growth of cancer cells along with being highly efficient and having high survival rates.
The boost in government initiatives to produce cancer medicine in the near future, rising prevalence of cancer incidences, and burgeoning partnerships of international market players with pharmaceutical industries are key factors expected to drive the growth of GCC Oncology/Cancer Drugs market. Moreover, key aspects such as extensive government spending toward the development of healthcare infrastructure due to a rise in non-communicable diseases such as cancer, launch of breast cancer awareness campaigns in the countries like UAE, and growing cancer burden on account of factors such as population growth and aging would further drive the demand for the drugs in the forthcoming years.
According to MarkNtel Advisors, the key players with a considerable market share in the GCC Oncology/Cancer Drugs market include Hoffmann-La Roche Ltd., Johnson & Johnson Middle East FZ LLC, Pfizer International Corporation, Merck Serono Middle East FZ-Ltd., AbbVie Biopharmaceuticals GmbH, AstraZeneca Gulf FZ LLC, Bayer Middle East FZE, Amgen, Inc., Astellas MENA/SSA etc.
Key Questions Answered in the Market Research Report:
Market Outlook, Segmentation and Statistics:
Frequently Asked Questions
Q. What is the historical year, base year, and forecast year considered in the research report on GCC Oncology/Cancer Drugs Market?
A. The historical data has been provided since 2015, while the base year is 2019 and the data is forecast up-to 2025.
Q. What are the units or denomination for measuring market value and volume in the report?
A. The market size/industry size or the market value is measured in terms of USD Million.
Q. What would be the growth rate or CAGR of the GCC Oncology/Cancer Drugs Market during 2020-25?
A. The growth rate of the GCC Oncology/Cancer Drugs Market during 2020-25 is forecast to grow at a considerable CAGR.
Q. Who are the key competitors or players operating in GCC Oncology/Cancer Drugs Market?
A. Hoffmann-La Roche Ltd., Johnson & Johnson Middle East FZ LLC, Pfizer International Corporation, Merck Serono Middle East FZ-Ltd., AbbVie Biopharmaceuticals GmbH, AstraZeneca Gulf FZ LLC, Bayer Middle East FZE, Amgen, Inc., Astellas MENA/SSA etc., are few of the leading players in the GCC Oncology/Cancer Drugs Market.
Q. Which application segment would emerge as an opportunity area for players in GCC Oncology/Cancer Drugs Market?
A. Breast Cancer is expected to attain the highest CAGR during the forecast period and maintain its significant market share.
Q. Which region would emerge as an opportunity area for players in GCC Oncology/Cancer Drugs Market?
A. UAE grabbed a significant market share continue to grow at the highest CAGR, presenting immense opportunities for market players of the GCC Oncology/Cancer Drugs Market.